Ranibizumab

證據等級: L5

預測適應症: 10 個

Ranibizumab: Repurposing Evaluation — No TxGNN Prediction Available

One-Sentence Summary

Ranibizumab is an anti-VEGF monoclonal antibody fragment known internationally under the brand name Lucentis, used primarily for ocular neovascular conditions such as wet age-related macular degeneration. The TxGNN model has not generated any predicted new indications for this drug in the current run, and no clinical trial or literature evidence is included in this Evidence Pack. This report reflects the current data availability and outlines what is needed before evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	None — TxGNN output not available
TxGNN Prediction Score	Not available
Evidence Level	L5 (Model prediction only — no actual studies linked)
Market Status	Not marketed (0 authorizations on record)
Number of Authorizations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is missing the four core inputs required for a repurposing evaluation — predicted indications, original indication text, mechanism of action, and safety profile. Without these, neither clinical plausibility nor risk assessment can be performed.

To proceed, the following is needed:

TxGNN prediction output — predicted_indications is currently an empty list; re-run the TxGNN pipeline for DB01270 and verify that the mapping step successfully linked Ranibizumab to disease nodes
Original indication data — original_indications is empty; retrieve approved indication text from the DrugBank entry or the package insert
Mechanism of action (MOA) — flagged as a High-severity data gap; query the DrugBank API for DB01270 to obtain the pharmacological mechanism
Safety data — key warnings and contraindications are missing; download and parse the package insert PDF to populate these fields
Regulatory status verification — confirm whether the 0-license result reflects the actual market status or a query coverage limitation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.